BRPI0919818A2 - inibidores de seprase seletivos - Google Patents
inibidores de seprase seletivosInfo
- Publication number
- BRPI0919818A2 BRPI0919818A2 BRPI0919818A BRPI0919818A BRPI0919818A2 BR PI0919818 A2 BRPI0919818 A2 BR PI0919818A2 BR PI0919818 A BRPI0919818 A BR PI0919818A BR PI0919818 A BRPI0919818 A BR PI0919818A BR PI0919818 A2 BRPI0919818 A2 BR PI0919818A2
- Authority
- BR
- Brazil
- Prior art keywords
- selective
- seprase
- inhibitors
- seprase inhibitors
- selective seprase
- Prior art date
Links
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 title 1
- 108010072257 fibroblast activation protein alpha Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10017808P | 2008-09-25 | 2008-09-25 | |
| PCT/US2009/058247 WO2010036814A1 (en) | 2008-09-25 | 2009-09-24 | Selective seprase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0919818A2 true BRPI0919818A2 (pt) | 2019-09-24 |
Family
ID=41305873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0919818A BRPI0919818A2 (pt) | 2008-09-25 | 2009-09-24 | inibidores de seprase seletivos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100098633A1 (pt) |
| EP (1) | EP2349995A1 (pt) |
| JP (1) | JP2012503670A (pt) |
| CN (1) | CN102203061A (pt) |
| AU (1) | AU2009296513A1 (pt) |
| BR (1) | BRPI0919818A2 (pt) |
| CA (1) | CA2737941A1 (pt) |
| RU (1) | RU2011116223A (pt) |
| TW (1) | TW201026335A (pt) |
| WO (1) | WO2010036814A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2240171B1 (en) | 2008-01-09 | 2014-08-13 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of carbonic anhydrase IX |
| EP2389361B1 (en) | 2008-12-05 | 2016-08-24 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma |
| WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
| WO2010065906A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer |
| BR112012000209B8 (pt) | 2009-06-15 | 2021-07-27 | Molecular Insight Pharm Inc | heterodímeros de ácido glutâmico e seus processos de preparação |
| US9120837B2 (en) | 2012-01-06 | 2015-09-01 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX |
| EP2866842A1 (en) * | 2012-06-29 | 2015-05-06 | GE Healthcare UK Limited | Imaging fibrosis |
| EP3545978B1 (en) | 2013-01-14 | 2021-09-08 | Molecular Insight Pharmaceuticals, Inc. | Triazine based radiopharmaceuticals and radioimaging agents |
| CN103992289B (zh) * | 2014-05-22 | 2016-04-06 | 河南全宇制药股份有限公司 | 取代噻唑烷氨荒酸铋配合物及其用途 |
| GB201613946D0 (en) * | 2016-08-15 | 2016-09-28 | Univ Oslo | Compounds |
| CN110291401B (zh) | 2016-12-14 | 2023-04-11 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| MA47215A (fr) | 2017-01-09 | 2019-11-13 | Bioxcel Therapeutics Inc | Procédés prédictifs et diagnostiques pour le cancer de la prostate |
| CN116617420A (zh) * | 2017-10-23 | 2023-08-22 | 约翰霍普金斯大学 | 靶向成纤维细胞活化蛋白α的化合物、药物组合物及用途 |
| WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| US20220273831A1 (en) | 2019-07-08 | 2022-09-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2021005131A1 (en) | 2019-07-08 | 2021-01-14 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2021195198A1 (en) * | 2020-03-24 | 2021-09-30 | Trustees Of Tufts College | Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto |
| CN112409414B (zh) * | 2020-12-01 | 2021-10-26 | 北京师范大学 | 锝-99m标记含异腈的FAPI衍生物及制备方法和应用 |
| EP4274835A1 (en) | 2021-01-07 | 2023-11-15 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5601801A (en) * | 1994-08-02 | 1997-02-11 | Merck Frosst Canada, Inc. | Radiolabelled angiotensin converting enzyme inhibitors |
| US20060093552A1 (en) * | 2002-03-11 | 2006-05-04 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof |
| EP1718342A4 (en) * | 2004-02-12 | 2009-07-22 | Molecular Insight Pharm Inc | TECHNETIUM AND RHENIUM-BIS (HETEROARYL) COMPLEXES AND APPLICATION METHODS |
| EP1943257A2 (en) * | 2005-05-19 | 2008-07-16 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| CN101594886A (zh) * | 2006-08-29 | 2009-12-02 | 分子制药洞察公司 | 偶合到用于成像表达肽酶的组织和器官的肽酶结合部分的放射影像部分 |
-
2009
- 2009-09-24 EP EP09792960A patent/EP2349995A1/en not_active Withdrawn
- 2009-09-24 CA CA2737941A patent/CA2737941A1/en not_active Abandoned
- 2009-09-24 JP JP2011529228A patent/JP2012503670A/ja not_active Withdrawn
- 2009-09-24 WO PCT/US2009/058247 patent/WO2010036814A1/en active Application Filing
- 2009-09-24 CN CN2009801403238A patent/CN102203061A/zh active Pending
- 2009-09-24 US US12/566,324 patent/US20100098633A1/en not_active Abandoned
- 2009-09-24 AU AU2009296513A patent/AU2009296513A1/en not_active Abandoned
- 2009-09-24 RU RU2011116223/04A patent/RU2011116223A/ru unknown
- 2009-09-24 BR BRPI0919818A patent/BRPI0919818A2/pt not_active IP Right Cessation
- 2009-09-25 TW TW098132489A patent/TW201026335A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102203061A (zh) | 2011-09-28 |
| AU2009296513A1 (en) | 2010-04-01 |
| RU2011116223A (ru) | 2012-10-27 |
| WO2010036814A1 (en) | 2010-04-01 |
| US20100098633A1 (en) | 2010-04-22 |
| JP2012503670A (ja) | 2012-02-09 |
| CA2737941A1 (en) | 2010-04-01 |
| EP2349995A1 (en) | 2011-08-03 |
| TW201026335A (en) | 2010-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020023I1 (el) | Αναστολεiς βητα-λακταμασων | |
| BRPI0919818A2 (pt) | inibidores de seprase seletivos | |
| CY2017016I2 (el) | Αναστολεις πρωτεασωματος | |
| BRPI0906764A2 (pt) | Processos | |
| BRPI0917808A2 (pt) | inibidores de cmet | |
| BRPI0919116A2 (pt) | método | |
| BRPI0907376A2 (pt) | Fotobiorretador | |
| DE602009000234D1 (de) | msignals | |
| BRPI0914649A2 (pt) | Piprazolo-quinazolinas | |
| DE602008003972D1 (de) | Sitzrücklehnungsmechanismus | |
| DE602008003521D1 (de) | Sitzrücklehnungsmechanismus | |
| BRPI0918564A2 (pt) | inibidores | |
| BRPI0814797A2 (pt) | Inibidores dna-pk | |
| DK2313489T3 (da) | Fremstillingsmetode | |
| DE602008003970D1 (de) | Strahlstromkalibriersystem | |
| BRPI0911625A2 (pt) | Métodos | |
| BRPI0907522A2 (pt) | biarlamidas | |
| DE112009001946A5 (de) | Mobelauszugsführung | |
| DE602009000488D1 (de) | Obstvereinzelvorrichtung | |
| DK2240506T3 (da) | IAP inhibitorer | |
| BRPI0907863A2 (pt) | pirrolopirimidinacarboxamidas | |
| BRPI0909637A2 (pt) | 2-aminoquinolinas | |
| DE112009000183A5 (de) | Sicherheitsvorreiber | |
| BRPI0916597A2 (pt) | Método | |
| DE602009000862D1 (de) | Gehwagenbremse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |